Bioconjugate polysaccharide vaccines
Founded in 2016 by Mario Feldman and Christian Harding, Omniose develops bioconjugate polysaccharide vaccines targeting bacterial pathogens using a proprietary glycoconjugation platform.
Ba'a sami bayanai ba
Ba'a sami tambayoyi ba.